Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis (HILT-ESCOA)

5 ottobre 2026 aggiornato da: Prof. Dr. Simin Hepgüler, Ege University

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial

This randomized, double-blind, sham-controlled clinical trial evaluated the effectiveness of high-intensity laser therapy (HILT) in patients with early-stage symptomatic knee osteoarthritis.

A total of 39 participants were randomly assigned to receive either HILT combined with a standardized home exercise program or sham laser therapy combined with the same exercise program. Laser or sham treatment was administered over 10 weekday sessions during a two-week period.

Participants were assessed at baseline, immediately after treatment, and at the three-month follow-up. Assessments included pain intensity, physical function, health-related quality of life, walking performance, knee range of motion, and muscle strength.

The aim was to determine whether adding HILT to exercise provides additional clinical benefits compared with sham laser therapy combined with exercise.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

39

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • İzmir
      • Izmir, İzmir, Turchia (Türkiye), 35100
        • Ege University Faculty of Medicine Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients presenting to the Physical Medicine and Rehabilitation outpatient clinics of Ege University Faculty of Medicine Hospital with knee pain lasting no longer than 6 months and a Visual Analog Scale (VAS) pain score of at least 4.
    2. Availability of bilateral weight-bearing knee radiographs in two views obtained within the preceding 6 months.
    3. Diagnosis of early symptomatic knee osteoarthritis according to the Italian Society of Rheumatology International Initiative (ESKOA) criteria.
    4. Ability to cooperate with the prescribed exercise program.
    5. Willingness to participate in the study and provision of informed consent.
    6. Age eligibility:
  • 40-49 years: Presence of at least one of the following risk factors for early symptomatic knee osteoarthritis.

  • 50-75 years: Eligible regardless of the presence of the listed risk factors.

Risk factors:

  • Body mass index (BMI) greater than 25 kg/m².
  • Family history of knee osteoarthritis.
  • Previous knee injury.
  • Lower-limb alignment abnormality.
  • Lower-limb length discrepancy.
  • Osteoarthritis at other anatomical sites.
  • Metabolic syndrome.
  • Difficulty initiating brisk walking or running after a period of inactivity.

Exclusion Criteria:

  1. Receipt of an intra-articular knee injection or physical therapy within the preceding 6 months, or use of natural health products such as glucosamine or chondroitin.

  2. History of knee surgery.

  3. Presence of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or gouty arthritis.

  4. History of trauma within the preceding 6 months.

  5. Fixed knee flexion deformity greater than 10 degrees or varus/valgus deformity greater than 15 degrees.

  6. Referred pain originating from the lumbar spine or hip.

  7. Neurological deficits affecting the lower extremities.

  8. Medical conditions that could prevent participation in the exercise program or completion of the study, including:

    • Myocardial infarction or cerebrovascular event within the preceding 3 months.
    • Congestive heart failure.
    • Severe chronic obstructive pulmonary disease.
    • History of myocardial ischemia during treadmill testing.
    • History of arterial or venous circulatory disorders.
  9. Presence of a cardiac pacemaker or metal implants.

  10. Pregnancy.

  11. History of malignancy, knee osteonecrosis, infectious disease, psychiatric illness, or bleeding diathesis.

  12. Epilepsy.

  13. Conditions impairing cooperation or communication, including language barriers, aphasia, marked affective disorders, or a history of severe psychiatric illness.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: HILT + Exercise

Participants received high-intensity laser therapy (HILT) combined with a standardized home exercise program. HILT was administered in 10 sessions over two consecutive weeks (five sessions per week). Participants also performed the prescribed home exercise program throughout the treatment period.

High-intensity laser therapy (HILT) was administered using a 1064-nm laser at a frequency of 20 Hz, with an energy density of 1530 mJ/cm² and a total energy of 3000 J per session. Treatment consisted of 10 sessions administered on consecutive weekdays over a two-week period. HILT was combined with a standardized home exercise program.

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Comparatore fittizio: Sham Laser + Exercise

Participants received sham laser therapy combined with the same standardized home exercise program as the experimental group. The sham procedure was administered without therapeutic laser energy in 10 sessions over two consecutive weeks (five sessions per week).

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Sham laser therapy was administered using the same treatment schedule and application procedure as the active HILT group, but without delivering therapeutic laser energy. Participants received 10 sham sessions over two consecutive weeks (five sessions per week), combined with the same standardized home exercise program.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain Intensity Assessed by Visual Analog Scale (VAS)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Pain intensity was assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Symptoms and Physical Function Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee osteoarthritis-related symptoms and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), including pain, stiffness, and physical function subscales. Higher scores indicate greater symptom severity and functional impairment.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Functional Status Assessed by Health Assessment Questionnaire (HAQ)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional status and activities of daily living were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). Scores range from 0 to 3, with higher scores indicating greater disability and poorer functional status.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Physical Component Summary (PCS)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Physical health-related quality of life was assessed using the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better physical health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Mental Component Summary (MCS)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Mental health-related quality of life was assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Functional Exercise Capacity Assessed by 6-Minute Walk Test (6MWT)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional exercise capacity was assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes was recorded in meters. A greater walking distance indicates better functional exercise capacity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Range of Motion (ROM)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee range of motion was assessed using a goniometer. Active and passive knee range of motion were measured in degrees.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Lower Extremity Muscle Strength Assessed by Manual Muscle Testing (MMT)
Lasso di tempo: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Lower extremity muscle strength was assessed using manual muscle testing (MMT). Muscle strength was graded on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Paracetamol Use
Lasso di tempo: Throughout the study period, from baseline to the 3-month follow-up

Paracetamol use was monitored using a patient diary to assess analgesic use during the study. Changes in paracetamol use were evaluated as an additional indicator of treatment effectiveness.

Throughout the study period, from baseline to the 3-month follow-up

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: A.Simin Hepgüler, MD, Ege University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 giugno 2025

Completamento primario (Effettivo)

18 gennaio 2026

Completamento dello studio (Effettivo)

18 gennaio 2026

Date di iscrizione allo studio

Primo inviato

30 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 settembre 2026

Primo Inserito (Effettivo)

6 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • EGE-PMR-HILT-2025-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval.

Periodo di condivisione IPD

De-identified individual participant data will be available upon reasonable request following publication of the manuscript.

Criteri di accesso alla condivisione IPD

De-identified individual participant data may be shared with qualified researchers upon reasonable request to the corresponding author (silaolmez@yahoo.com.tr), subject to ethical and institutional approval.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .